Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ROC-101
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Versant Ventures
Deal Size : $50.0 million
Deal Type : Series A Financing
AllRock Bio Raises $50 million to Drive Therapy for Pulmonary Hypertension into Phase 2
Details : The proceeds will advance AllRock's lead molecule, ROC-101, a first-in-class, oral ROCK inhibitor, which the company exclusively licensed from Sanofi, into Phase 2 clinical development.
Product Name : ROC-101
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 16, 2025
Lead Product(s) : ROC-101
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Versant Ventures
Deal Size : $50.0 million
Deal Type : Series A Financing